Candan, O. Et Al. 2023. The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia. Annals of Hematology , vol.102, no.12 , 3647-3648.

Candan, O., Demirtas, D., YANIK, A. M., ATAGÜNDÜZ, I., & TOPTAŞ, T., (2023). The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia. Annals of Hematology , vol.102, no.12, 3647-3648.

Candan, Ozlem Et Al. "The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia," Annals of Hematology , vol.102, no.12, 3647-3648, 2023

Candan, Ozlem Et Al. "The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia." Annals of Hematology , vol.102, no.12, pp.3647-3648, 2023

Candan, O. Et Al. (2023) . "The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia." Annals of Hematology , vol.102, no.12, pp.3647-3648.

@article{article, author={Ozlem Candan Et Al. }, title={The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia}, journal={Annals of Hematology}, year=2023, pages={3647-3648} }